Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myriad Pharmaceuticals, a biopharmaceutical company, has received the FDA approval for the company's investigational new drug or IND application to begin a Phase I clinical study with its Hsp90 inhibitor, MPC-3100, for the treatment of cancer.
Subscribe to our email newsletter
The clinical development plan for MPC-3100 is designed to expedite the drug candidate through the clinical development path. The Phase I trial will assess the safety and pharmacokinetics profile of MPC-3100.
In preclinical testing, MPC-3100 has demonstrated potent anticancer activity in xenograft models of Her2+ breast cancer, myeloid leukemia, lung cancer, prostate cancer, colon cancer, melanoma and gastric cancer, said Myriad.
Adrian Hobden, president of Myriad Pharmaceuticals, said: “MPC-3100 shows tremendous potential for the treatment of a wide range of cancers. The compound is the fifth new chemical entity to emerge from the company’s internal discovery efforts and enter clinical study. We believe MPC-3100 will be an exciting addition to Myriad Pharmaceutical’s clinical pipeline.”